A public-private consortium advances cardiac safety evaluation: achievements of the HESI Cardiac Safety Technical Committee.
J Pharmacol Toxicol Methods 2013;
68:7-12. [PMID:
23567075 DOI:
10.1016/j.vascn.2013.03.008]
[Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Revised: 03/25/2013] [Accepted: 03/26/2013] [Indexed: 10/27/2022]
Abstract
INTRODUCTION
The evaluation of cardiovascular side-effects is a critical element in the development of all new drugs and chemicals. Cardiac safety issues are a major cause of attrition and withdrawal due to adverse drug reactions (ADRs) in pharmaceutical drug development.
METHODS
The evolution of the HESI Technical Committee on Cardiac Safety from 2000-2013 is presented as an example of an effective international consortium of academic, government, and industry scientists working to improve cardiac safety.
RESULTS AND DISCUSSION
The HESI Technical Committee Working Groups facilitated the development of a variety of platforms for resource sharing and communication among experts that led to innovative strategies for improved drug safety. The positive impacts arising from these Working Groups are described in this article.
Collapse